Budigalimab vs Penpulimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Budigalimab

Developed by AbbVie

Phase 2/3 in Non-Small Cell Lung Cancermonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT03893955 (registry estimate)

No aligned efficacy figure on record for this race.

Penpulimab

Marketed by Akeso and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03866993 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.

Reported efficacy

Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)

Result source: NCT03866993

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBudigalimabPenpulimab
PFS, median—Trial running · NCT062364388.6 vs 4.2a+4.4 vs placeboNCT03866993
OS, median—Trial running · NCT06236438—Not posted · NCT03866993
ORR—Trial running · NCT06236438—Not posted · NCT03866993
Duration of response, median—Trial running · NCT06236438—Not posted · NCT03866993

PFS, median

Budigalimab
—Trial running · NCT06236438
Penpulimab
8.6 vs 4.2a+4.4 vs placeboNCT03866993

OS, median

Budigalimab
—Trial running · NCT06236438
Penpulimab
—Not posted · NCT03866993

ORR

Budigalimab
—Trial running · NCT06236438
Penpulimab
—Not posted · NCT03866993

Duration of response, median

Budigalimab
—Trial running · NCT06236438
Penpulimab
—Not posted · NCT03866993
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Budigalimab: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Penpulimab

PFS 8.6 vs 4.2 placebo months
time to event · months
NCT03866993 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budigalimab's landscape · Penpulimab's landscape